What Is Semax?
Semax was created in 1982 by a research team led by academicians Nikolai Myasoedov and Igor Ashmarin at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. Their work built on decades of research showing that ACTH fragments, particularly the 4-7 and 4-10 residue sequences, possessed potent nootropic and neurotrophic activity independent of the adrenal hormonal effects associated with full-length ACTH. The challenge was that these short peptide fragments degraded rapidly in biological systems, lasting only minutes in plasma before enzymatic cleavage rendered them inactive.
The solution was the addition of Pro-Gly-Pro to the C-terminus of the ACTH(4-7) fragment. This tripeptide is itself a fragment of proline-rich peptides involved in immune regulation, and its attachment dramatically extended the biological half-life of the core sequence while contributing independent anti-inflammatory properties. The resulting compound, Semax, retained the nootropic and neurotrophic effects of the ACTH fragment while resisting enzymatic degradation long enough for clinical utility through intranasal administration.Semax was initially pursued as a treatment for stroke patients suffering ischemic brain damage. Over more than a decade of preclinical and clinical study in Russia, its indications expanded. The Russian Federation approved Semax in two formulations: a 0.1% intranasal solution for cognitive enhancement, memory disorders, and general neuroprotection, and a 1% intranasal solution for acute neurological conditions including ischemic stroke and optic nerve disease. It was formally added to the Russian List of Vital and Essential Drugs on December 7, 2011.
Critically, Semax is devoid of hormonal activity. Despite its derivation from ACTH, the heptapeptide does not stimulate adrenal cortisol release or engage the hypothalamic-pituitary-adrenal axis. Its biological activity is confined to neurotrophic, neuroprotective, and immunomodulatory pathways, a deliberate design outcome that distinguishes it from its parent hormone.How It Works
Semax acts through multiple converging mechanisms that collectively support neuronal survival, synaptic plasticity, and neurotransmitter balance. The breadth of its pharmacological profile reflects the multifunctionality of melanocortin-derived peptides, which interact with diverse receptor systems and intracellular signaling cascades.
BDNF and Neurotrophic Factor Upregulation
The most extensively documented mechanism of Semax is its potent upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Intranasal administration of Semax significantly increases BDNF mRNA expression in the rat hippocampus and frontal cortex within 30 to 90 minutes, with effects persisting for several hours.
This upregulation occurs through activation of the cAMP response element-binding protein (CREB) pathway. CREB is a transcription factor that, when phosphorylated, drives expression of neurotrophin genes including BDNF and NGF. The resulting increase in BDNF levels activates the tropomyosin receptor kinase B (TrkB) receptor, initiating downstream signaling cascades through the MAPK/ERK, PI3K/Akt, and PLCgamma pathways. These cascades promote synaptic strengthening, dendritic branching, neurogenesis, and long-term potentiation, the cellular substrate of learning and memory.
In cerebral ischemia models, Semax treatment promoted earlier upregulation of BDNF, TrkC, and TrkA genes while preventing the ischemia-induced decline in NT-3 and NGF transcription. This neurotrophic rescue effect is a primary mechanism underlying Semax's neuroprotective properties in stroke.
Dopaminergic and Serotonergic Modulation
Semax modulates both dopaminergic and serotonergic neurotransmission, though its effects are more modulatory than directly stimulatory. For users exploring Semax alongside immune-focused peptides, Thymosin Alpha 1 is a commonly combined option given its complementary immunomodulatory profile. Studies using in vivo microdialysis in rodents demonstrated that Semax alone did not significantly alter basal dopamine or serotonin concentrations in the striatum. However, serotonin metabolite (5-HIAA) levels gradually increased to approximately 180% of baseline within one to four hours after Semax administration, indicating enhanced serotonergic turnover.
The more striking finding involved dopamine modulation under stimulated conditions: when Semax was administered 20 minutes prior to d-amphetamine, it dramatically enhanced the amphetamine-induced increase in extracellular dopamine levels and locomotor activity. This suggests Semax sensitizes or primes dopaminergic neurons without directly flooding the synapse with dopamine, a pharmacological profile more consistent with adaptive enhancement than with stimulant-like activity.
This dual neurotransmitter modulation likely contributes to the subjective improvements in focus, motivation, and mood stability reported with Semax use, and provides a mechanistic rationale for its investigation in attention-deficit conditions. Semax is one of the top-ranked options in the best peptides for cognitive enhancement guide.
Neuroprotective Mechanisms
In models of cerebral ischemia-reperfusion, Semax exerts broad neuroprotective effects at both the genomic and proteomic levels. Genome-wide transcriptional analysis following experimental stroke in rats revealed that Semax significantly altered the expression of genes related to immune, vascular, and neurotransmitter systems.
At the protein level, 24 hours after transient middle cerebral artery occlusion, Semax treatment resulted in upregulation of active CREB in subcortical structures, downregulation of matrix metalloproteinase-9 (MMP-9) in the adjacent frontoparietal cortex, and downregulation of active JNK (c-Jun N-terminal kinase) in both tissues. MMP-9 downregulation is particularly significant because MMP-9 contributes to blood-brain barrier breakdown after ischemia, and JNK is a key mediator of apoptotic cell death pathways. Semax also binds copper(II) ions with high affinity, which may contribute antioxidant effects by preventing copper-catalyzed oxidative damage in ischemic tissue.
Immune and Anti-Inflammatory Effects
Semax suppresses the transcription of major pro-inflammatory mediators induced by ischemia-reperfusion, including Il1a, Il1b, Il6, Ccl3, and Cxcl2. This anti-inflammatory action compensates for the surge of inflammatory cytokines that occurs following ischemic injury and contributes to reduced secondary brain damage.
Simultaneously, Semax enhances aspects of adaptive immunity. It activates antigen presentation signaling pathways, intensifies interferon signaling, and affects immunoglobulin synthesis. Immunobiochemical analysis of cerebrospinal fluid in stroke patients receiving Semax demonstrated a shift in neuromodulatory balance toward anti-inflammatory agents (interleukin-10, transforming growth factor-beta) and away from pro-inflammatory factors (interleukin-8, C-reactive protein).
Under chronic social stress conditions, Semax also modulated levels of IL-1beta, IL-4, IL-6, TNF-alpha, and TGF-beta1, suggesting immunomodulatory activity that extends beyond acute ischemic contexts.